TCL Archive Cancer Policy: EMFs “Possible” Carcinogen, Panel Says; Plans Public Hearings August 7, 1998
TCL Archive Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light December 5, 2014
TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive CTEP’s Clinical Trials Proposals Reshaped By Discussion: BSC Next On Schedule May 9, 1986
TCL Archive NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study. June 3, 2005
